西藏塑像研究与保护中的宗教和伦理问题

前言研究和保护西藏塑像涉及许多复杂的问题，部分原因是由于这些作品的制作并非完全出于美学的目的，作品在严肃的西藏宗教活动中发挥着各种功能。对于密宗塑像来说，多种功能甚至是共同的。密宗塑像是用来传授秘密教义的，密咒本续文献中有载。就是这些塑像向学者和保护者们提出了最复杂的问题和伦理的窘境。在西方现存的收藏品中，这些塑像难以被忽视。不管怎样，有一些明确的步骤使保护专家可以从事对西藏佛教塑像的研究，并且保证伦理的选择被充分地考虑了。西藏宗教活动中偶像塑像的作用1．佛教塑像佛教涉及怜悯的发展和对无的认识及…     

历史上的大流感

自古以来，瘟疫就经常给人类带来巨大的灾难。流感便是其中主要的一种。流感一般分为三种，即甲型、乙型和丙型。甲型流感也就是目前向人类发起新挑战的禽流感。让我们翻开人类疾病的历史，看看历史上的流感是怎样的。     

分享雅致生活

如果我们在生活中坚持创造富有意义的个人情趣，那么我们就能够摆脱乏味的日常生活，丰富自己的经历，提升自己的品位；同时还能给身心带来舒适和安宁。情趣为我们创造了领恬生命真谛的机会，使我们有机会欣赏和创造羡，使我们珍惜生命中的每一天，使我们拥有无数美好的回忆。长此以往，生活中的平庸琐碎之事将被渐渐淡忘，留在脑海中的只有具有积极意义的特殊时光。     

现代国际贸易理论中的国内和国际规模收益

在二战后的国际贸易中,工业化国家之间的制造业产品的交易量巨大,这种产业内贸易现象的出现,在一定程度上对传统的赫克歇尔-俄林-萨缪尔逊贸易模型产生了冲击和质疑。经济学家从多个角度寻求对这种现象的理论解释,并开始注意产品差别化及其对规模经济的影响,但是,这些研究对贸易理论的影响很小,并且解释现实的能力也很弱。因此,把差别化的生产资料作为研究的重点,在国际收益的框架下,建立模型以推出国际规模收益,并且运用这一模型得出了国际规模收益、传统的国内规模收益和要素禀赋论之间的关系。     

Average life expectancy of the population of the USSR

Mortality trends in the USSR from the middle of the nineteenth century to the present day are analyzed, with a focus on changes in life expectancy. The authors note that life expectancy increased up to 1964-1965, declined subsequently, and stabilized during the 1980s. Life expectancy has again started to rise since 1985. More detailed analyses of mortality differentials by sex and age and for the rural and urban populations are included. (SUMMARY IN ENG)     

Taikongs and Calos: the role of middlemen and brokers in Javanese international migration

"This article discusses international migration from Java in the past and present and the role brokers have played in stimulating this movement. It describes legal and clandestine labor migration to Singapore, Malaysia, and Saudi Arabia, the influence of employment brokers on the process, and the organization of the recruitment networks. The involvement of brokers is crucial but not always beneficial for the migrants. Migrants are dependent on the brokers and risk exploitation. In the case of movement to Saudi Arabia, there is a linkage with religious institutions and the Islamic pilgrimage."     

The mandate for investigational cancer therapies

The heated national health care reform debate of the summer of 1993 has now simmered down, but pieces of the debate are still percolating along at the state level. Within the past year, numerous states have introduced bills that would mandate insurance coverage for investigational cancer therapies--in particular high-dose chemotherapy and bone marrow transplant for breast cancer. The problem with these initiatives, well-intended though they may be, is that they threaten to spread unproven technologies at a rapid rate and at the same time miss the opportunity to collect data that would prove the safety and effectiveness of the methods. The author explores these issues and suggests how managed care companies can play a more aggressive role in parrying the threat.